Each year, nearly 40,000 Americans undergo elective surgery to repair an abdominal aortic aneurysm (AAA) with the goal of preventing a life-threatening rupture of this potentially dangerous cardiovascular condition. A new study from researchers at Beth Israel Deaconess Medical Center, Boston, USA, compared open surgical repair with a catheter-based procedure and found that the less invasive endovascular aortic repair (EVAR) has clear benefits for most patients, providing both a safer operation and a quicker recovery. The study was published in The New England Journal of Medicine.
Metactive announced that it has received a phase I National Institutes of Health (NIH) grant to fund comparative studies of its embolization device, Blockstent microcatheter.
Preclinical research published online ahead of print in the Journal of Vascular and Interventional Radiology (JVIR) in July shows that combretastatin A4 is a stronger inhibitor of the smooth muscle cell cycle than sirolimus or paclitaxel. Thus, it may represent an alternative coating for drug-eluting stents and balloons in atherosclerotic luminal stenosis, the investigators write.
Results from the 9th Annual Survey on Observational Research conducted by Continuum Clinical suggest that the pharmaceutical, biotech, and medical device industries are aware of the benefits of observational research in better understanding the real world value of their products. However, they also show that there is continued need to improve the design and implementation of the studies.
Guerbet has announced entering into a definitive agreement under which it will acquire Mallinckrodt’s contrast media and delivery systems business in its entirety for approximately US$270 million. With this acquisition, Guerbet aims to create a new global leader in medical imaging.
Two new studies presented at the Society of NeuroInterventional Surgery 12th Annual Meeting in San Francisco, USA, report that Mobile Stroke Treatment Units (MSTUs) can significantly reduce the time it takes to diagnose and treat patients for stroke, greatly improving survival rates and enhancing a patient’s chance of recovery.
Spectranetics has received US Food and Drug Administration 510(k) clearance for the AngioSculpt percutaneous transluminal angioplasty (PTA) scoring balloon catheter in 7mm and 8mm diameter balloon sizes, designed to treat the narrowing of the native or synthetic fistula.
Veryan Medical has announced that the first subject has been enrolled in its MIMICS-2 study at Universitäts-Herzzentrum Freiburg in Bad Krozingen, Germany, by the European principal investigator, Thomas Zeller.
The first clinical cases using Lombard Medical’s new Aorfix Plus endovascular stent graft have been successfully completed.
Jan Heyligers and Patrick Vriens, Tilburg, The Netherlands, write about a technique using the great saphenous vein for the reconstruction of an infected aorta. The technique, defined as a “see one, do one” procedure, was presented at the Charing Cross Symposium in April.
The widely varying progressions of cancer require comprehensive diagnostics, an early check of treatment, and the exchange of information with colleagues. Siemens says that its new version of the diagnostics software syngo.via supports the treating physician in making decisions regarding treatment in oncology through a comprehensive portfolio of applications across imaging systems, treatments, and disciplines.
Hansen Medical has announced it will exhibit its Magellan Robotic System at the Global Embolization Symposium and Technologies (GEST) Scientific Meeting 24–27 June at the FIBES II New Conference Centre in Seville, Spain.
While there is a trend towards using smaller sized particles to obtain better results with embolization, clinical and research experts at the recently held Global Embolization Symposium and Technologies (GEST EU; 24–27 June, Seville, Spain) agreed that there appeared to be a lower size limit, <100µm, below which drug-eluting beads did not have an effective embolic effect.
A study of 311 patients by The University of Manchester has found that it may be possible to predict early which rheumatoid arthritis (RA) patients will fail to respond to the biologic drugs given to treat them. These findings could help better manage patients symptoms.
A petite 44-year-old woman has received a successful heart transplant at Ronald Reagan UCLA Medical Center, thanks to an experimental Total Artificial Heart designed for smaller patients. The UCLA patient is the first person in California to receive the smaller Total Artificial Heart, and the first patient in the world with the device to be bridged to a successful heart transplant - that is, to go from needing a transplant to receiving one.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos